The DOI matches its Crossref record; 33 of the 36 references it cites were found in a registry or an index.
Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
Open accessAbstract
Background To evaluate the efficacy and feasibility of rituximab monotherapy in Japanese patients with relapsed or refractory aggressive B-cell lymphoma.Patients and methods Sixty-eight patients were treated with rituximab at 375 mg/m(2) by eight consecutive weekly infusions. Pretreatment variables affecting overall response rate (ORR) and progression-free survival (PFS) and the relationship between pharmacokinetic parameters and efficacy were analyzed.Results The ORRs of 68 enrolled patients and 57 eligible patients were 35% [95% confidence interval (CI) 24% to 48%] and 37% (95% CI 25% to 51%), respectively. Median PFS of 53 evaluable patients was 52 days, whereas time to progression of 21 eligible responders was 245 days. Mild to moderate infusion-related toxicities were observed frequently at the first infusion, but all of them were reversible. Elevated lactate dehydrogenase (LDH) and refractoriness to prior chemotherapy were unfavorable factors affecting ORR and PFS (P <0.01). Serum trough levels of rituximab and area under the concentration-time curve for responders were higher than for non-responders (P <0.05).Conclusions Eight consecutive weekly infusions of rituximab have significant anti-lymphoma activity for relapsed or refractory aggressive B-cell lymphoma. Several pretreatment variables and serum rituximab levels are useful for predicting its efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous comparisons of different dosing regimens [75, 76] revealed that trastuzumab or rituximab Cmax did not correlate with clinical efficacy.”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Harris, N. L., Jaffe, E., Stein, H., Pm, B., Jk, C., Cleary, M. L., Delsol, G., Peeters, C., Falini, B., & Gatter, K. C. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,312
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,950
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
McLaughlin, P. J., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence‐Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,752
Cited by
Sorted by citations
Items 101–108 of 108
Böhnke, A., & Wenger, M. (2014) · doi:10.1002/9783527682423.ch70
Wenger, M. (2007) · doi:10.1002/9783527619740.ch39
Therapeutic monoclonal antibodies in clinical laboratory
Malíčková, K. (2017) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2017.020
To PET or not to PET, that is the question
Suzuki, R. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.008
Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?
Arrivé, C., Hotot, M., Jourdil, J., & Stanke‐Labesque, F. (2026) · BioDrugs · doi:10.1007/s40259-026-00790-0
Horaguchi, R., Kikuchi, S., Ono, K., Minemura, T., & Sato, T. (2026) · Reports — Medical Cases Images and Videos · doi:10.3390/reports9030318
Metadata
- Authors
- Tobinai, K., Igarashi, T., Itoh, K., Kobayashi, Y., Taniwaki, M., Ogura, M., Kinoshita, T., Hotta, T., Aikawa, K., Tsushita, K., Hiraoka, A., Matsuno, Y., Nakamura, S., Mori, S., & Ohashi, Y.
- Affiliations
- National Cancer Center Hospital (JP)
- National Cancer Center Hospital East (JP)
- Kyoto Prefectural University of Medicine (JP)
- Aichi Cancer Center (JP)
- Nagoya University Hospital (JP)
- Tokai University (JP)
- Sapporo National Hospital (JP)
- Higashi Nagoya National Hospital (JP)
- Osaka International Cancer Institute (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Corresponding author
- Tobinai, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2004-05
- Volume
- 15
- Issue
- 5
- Pages
- 821-830
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2114676941
- Cited by
- 108
- References
- 36
- Citations by year
- 2026: 3 · 2025: 1 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 7 · 2016: 5 · 2015: 6 · 2014: 7 · 2013: 4 · 2012: 6
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- IC Design Education Center
- Fujita Health University
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- rituximab, relapsed or refractory B-cell lymphoma, aggressive B-cell lymphoma, rituximab monotherapy, pharmacokinetics, trough concentration, area under the concentration-time curve, overall response rate, progression-free survival, lactate dehydrogenase, infusion-related toxicity, Japanese patients, predictive biomarkers
- MeSH terms
- Rituximab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Lymphoma, B-Cell, Disease-Free Survival, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
